News Release

IDIBELL researchers identify a new leukodystrophy in children and its potential cure

The gene that causes the disease is called DEGS1 and its defect may be counteracted with fingolimod, a drug currently used to treat multiple sclerosis

Peer-Reviewed Publication

IDIBELL-Bellvitge Biomedical Research Institute


image: Aurora Pujol's team view more 


The Neurometabolic Diseases research team at IDIBELL and CIBER of Rare Diseases (CIBERER), led by ICREA Professor Aurora Pujol, has uncovered a novel disease of children affecting the brain white matter -the myelin sheath-, leading to severe incapacity and death in some cases.

The gene causing the disorder is called DEGS1 and was identified using whole exome sequencing (WES) of 19 patients from around the globe (China, Iran, Morocco, USA, and France). "Sample collection for such a rare disease was extremely fast thanks to our collaboration with reference centers for leukodystrophies in France (Dr Odile Boespflug-Tanguy) and in Baltimore (Dr Ali Fatemi), and to the freely accessible genomic information exchange platform GeneMatcher", Dr Pujol explains.

DEGS1 is an enzyme of lipid metabolism that converts dihydroceramides to ceramides, at a hub essential for brain function. Indeed, defects in other enzymes along this pathway cause similar rare diseases like Krabbe disease or Metachromatic Leukodystrophy, also affecting the myelin..

A zebrafish model with deficient DEGS1 function was generated in the laboratory of Dr Cristina Pujades, UPF Barcelona, and exhibited swimming difficulties, loss of myelin forming cells (oligodendrocytes) and ceramide imbalances. These defects were corrected by a treatment with fingolimod, a drug in use for multiple sclerosis which interferes with this pathway. "These results pave the way to clinical trials, illustrating the transformative impact of clinical and functional genomics in the continuum from diagnostics to treatment", adds Dr Pujol.


The research has been published in the high impact journal Journal of Clinical Investigation, and received funds from La Marató de TV3, the Spanish National Institutes of Health Carlos III (FIS), the Hesperia Foundation, CIBERER and ELA-España. Dr Pujol leads CIBERER U-759 unit.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.